Does the Use of Neoadjuvant Therapy for Pancreatic Adenocarcinoma Increase Postoperative Morbidity and Mortality Rates?

Journal of Gastrointestinal Surgery

Volumn 19, Issue 1, 2015, Pages 80-87

  Cooper, Amanda B ^a   Parmar, Abhishek D ^b   Riall, Taylor S ^b   Hall, Bruce L ^c   Katz, Matthew H G ^d   Aloia, Thomas A ^d   Pitt, Henry A ^e  

^a PENNSYLVANIA STATE UNIVERSITY   (United States)

^b University of Texas Medical Branch School of Medicine   (United States)

^c BJC HEALTHCARE   (United States)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^e TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Neoadjuvant chemoradiation; Neoadjuvant chemotherapy; Pancreatectomy; Pancreatic fistula

Indexed keywords

ADENOCARCINOMA; ADULT; AGED; CLINICAL TRIAL; FEMALE; HUMAN; MALE; MIDDLE AGED; MORBIDITY; MULTICENTER STUDY; NEOADJUVANT THERAPY; PANCREAS RESECTION; PANCREATIC NEOPLASMS; POSTOPERATIVE PERIOD; PROSPECTIVE STUDY; SURVIVAL RATE; TREATMENT OUTCOME; TRENDS; UNITED STATES; VERY ELDERLY; YOUNG ADULT;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; MALE; MIDDLE AGED; MORBIDITY; NEOADJUVANT THERAPY; PANCREATECTOMY; PANCREATIC NEOPLASMS; POSTOPERATIVE PERIOD; PROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME; UNITED STATES; YOUNG ADULT;

EID: 84939465687     PISSN: 1091255X     EISSN: 18734626     Source Type: Journal    
DOI: 10.1007/s11605-014-2620-3     Document Type: Article

References (24)

1. Tempero, MA, Arnoletti, JP, Behrman, SW, et al. Pancreatic Adenocarcinoma, version 2.2012: featured updates to the NCCN Guidelines. J Natl Compr Canc Netw. 2012;10: 703-713.
2. Parmar AD, VG, Tamirisa NP, Sheffield KM, Riall TS. Trajectory of Care and Use of Multimodality Therapy in Locoregional Pancreatic Adenocarcinoma. Surgery.2014;156:280-9.
3. Weese, JL, Nussbaum, ML, Paul, AR, et al. Increased resectability of locally advanced pancreatic and periampullary carcinoma with neoadjuvant chemoradiotherapy. Int J Pancreatol. 1990;7: 177-185.
4. Jessup, JM, Steele, G, Jr., Mayer, RJ, et al. Neoadjuvant therapy for unresectable pancreatic adenocarcinoma. Arch Surg. 1993;128: 559-564.
5. Yeung, RS, Weese, JL, Hoffman, JP, et al. Neoadjuvant chemoradiation in pancreatic and duodenal carcinoma. A Phase II Study. Cancer. 1993;72: 2124-2133.
6. Evans, DB, Varadhachary, GR, Crane, CH, et al. Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head. J Clin Oncol. 2008;26: 3496-3502.
7. Varadhachary, GR, Wolff, RA, Crane, CH, et al. Preoperative gemcitabine and cisplatin followed by gemcitabine-based chemoradiation for resectable adenocarcinoma of the pancreatic head. J Clin Oncol. 2008;26: 3487-3495.
8. Cetin, V, Piperdi, B, Bathini, V, et al. A Phase II Trial of Cetuximab, Gemcitabine, 5-Fluorouracil, and Radiation Therapy in Locally Advanced Nonmetastatic Pancreatic Adenocarcinoma. Gastrointest Cancer Res. 2013;6: S2-9.
9. Lee, JL, Kim, SC, Kim, JH, et al. Prospective efficacy and safety study of neoadjuvant gemcitabine with capecitabine combination chemotherapy for borderline-resectable or unresectable locally advanced pancreatic adenocarcinoma. Surgery. 2012;152: 851-862.
10. Landry, J, Catalano, PJ, Staley, C, et al. Randomized phase II study of gemcitabine plus radiotherapy versus gemcitabine, 5-fluorouracil, and cisplatin followed by radiotherapy and 5-fluorouracil for patients with locally advanced, potentially resectable pancreatic adenocarcinoma. J Surg Oncol. 2010;101: 587-592.
11. Pitt, HA, Kilbane, M, Strasberg, SM, et al. ACS-NSQIP has the potential to create an HPB-NSQIP option. HPB (Oxford). 2009;11: 405-413.
12. Parikh, P, Shiloach, M, Cohen, ME, et al. Pancreatectomy risk calculator: an ACS-NSQIP resource. HPB (Oxford). 2010;12: 488-497.
13. Parmar, AD, Sheffield, KM, Vargas, GM, et al. Factors associated with delayed gastric emptying after pancreaticoduodenectomy. HPB (Oxford). 2013;15: 763-772.
14. User Guide for the 2010 Participant Use Data File. [American College of Surgeons National Surgical Quality Improvement Program]. Available from URL: http://site.acsnsqip.org/wp-content/uploads/2012/03/ACS-NSQIP-Participant-User-Data-File-User-Guide_06.pdf. [accessed January, 2013.
15. Fang, Y, Gurusamy, KS, Wang, Q, et al. Pre-operative biliary drainage for obstructive jaundice. Cochrane Database Syst Rev. 2012;9: CD005444.
16. Sewnath, ME, Karsten, TM, Prins, MH, et al. A meta-analysis on the efficacy of preoperative biliary drainage for tumors causing obstructive jaundice. Ann Surg. 2002;236: 17-27.
17. van der Gaag, NA, Rauws, EA, van Eijck, CH, et al. Preoperative biliary drainage for cancer of the head of the pancreas. N Engl J Med. 2010;362: 129-137.
18. Araujo, RL, Gaujoux, S, Huguet, F, et al. Does pre-operative chemoradiation for initially unresectable or borderline resectable pancreatic adenocarcinoma increase post-operative morbidity? A case-matched analysis. HPB (Oxford). 2013;15: 574-580.
19. Pecorelli, N, Braga, M, Doglioni, C, et al. Preoperative chemotherapy does not adversely affect pancreatic structure and short-term outcome after pancreatectomy. J Gastrointest Surg. 2013;17: 488-493.
20. Laurence, JM, Tran, PD, Morarji, K, et al. A systematic review and meta-analysis of survival and surgical outcomes following neoadjuvant chemoradiotherapy for pancreatic cancer. J Gastrointest Surg. 2011;15: 2059-2069.
21. Takahashi, H, Ogawa, H, Ohigashi, H, et al. Preoperative chemoradiation reduces the risk of pancreatic fistula after distal pancreatectomy for pancreatic adenocarcinoma. Surgery. 2011;150: 547-556.
22. Birkmeyer, JD, Dimick, JB. Potential benefits of the new Leapfrog standards: effect of process and outcomes measures. Surgery. 2004;135: 569-575.
23. Allareddy, V, Ward, MM, Allareddy, V, Konety, BR. Effect of meeting Leapfrog volume thresholds on complication rates following complex surgical procedures. Ann Surg. 2010;251: 377-383.
24. Roberts, KJ, Storey, R, Hodson, J, et al. Pre-operative prediction of pancreatic fistula: is it possible? Pancreatology. 2013;13: 423-428.